slc22a1

slc22a1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc22a1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC22A1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 22 Member 1 (OCT1)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Organic Cation Transporter 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.4</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[6579](https://www.ncbi.nlm.nih.gov/gene/6579)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607607](https://www.omim.org/entry/607607)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000175084</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[O15245](https://www.uniprot.org/uniprot/O15245)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>554 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Alzheimer's Disease, Drug Transport at BBB</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.4</td>
</tr>
<tr>
<td class="label">Genomic Size</td>
<td>~27 kb</td>
</tr>
<tr>
<td class="label">Exon Count</td>
<td>12</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>554 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</

slc22a1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc22a1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC22A1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 22 Member 1 (OCT1)</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Organic Cation Transporter 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.4</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[6579](https://www.ncbi.nlm.nih.gov/gene/6579)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[607607](https://www.omim.org/entry/607607)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000175084</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[O15245](https://www.uniprot.org/uniprot/O15245)</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>554 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>Parkinson's Disease, Alzheimer's Disease, Drug Transport at BBB</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q13.4</td>
</tr>
<tr>
<td class="label">Genomic Size</td>
<td>~27 kb</td>
</tr>
<tr>
<td class="label">Exon Count</td>
<td>12</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>554 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~61 kDa</td>
</tr>
<tr>
<td class="label">Transmembrane Domains</td>
<td>12</td>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Location</td>
</tr>
<tr>
<td class="label">OCT1</td>
<td>Luminal membrane</td>
</tr>
<tr>
<td class="label">OCT2</td>
<td>Luminal membrane</td>
</tr>
<tr>
<td class="label">OCT3</td>
<td>Abluminal membrane</td>
</tr>
<tr>
<td class="label">MATEs</td>
<td>Luminal membrane</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>OCT1 Transport</td>
</tr>
<tr>
<td class="label">Cholinesterase inhibitors</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">NMDA receptor antagonists</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">Aβ-targeting antibodies</td>
<td>No</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Function</td>
</tr>
<tr>
<td class="label">R61C</td>
<td>Loss-of-function</td>
</tr>
<tr>
<td class="label">P341L</td>
<td>Reduced activity</td>
</tr>
<tr>
<td class="label">G401S</td>
<td>Normal function</td>
</tr>
<tr>
<td class="label">V501F</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Interaction Type</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Substrates</td>
<td>Metformin, morphine, dopamine</td>
</tr>
<tr>
<td class="label">Inhibitors</td>
<td>Cimetidine, quinine</td>
</tr>
<tr>
<td class="label">Inducers</td>
<td>Rifampin</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">OCT1 agonists</td>
<td>Increase drug uptake</td>
</tr>
<tr>
<td class="label">OCT1 inhibitors</td>
<td>Reduce neurotoxicity</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Modulate expression</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">SLC22A1</td>
<td>OCT1</td>
</tr>
<tr>
<td class="label">SLC22A2</td>
<td>OCT2</td>
</tr>
<tr>
<td class="label">SLC22A3</td>
<td>OCT3</td>
</tr>
<tr>
<td class="label">SLC22A4</td>
<td>OCTN1</td>
</tr>
<tr>
<td class="label">SLC22A5</td>
<td>OCTN2</td>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Location</td>
</tr>
<tr>
<td class="label">OCT1</td>
<td>Luminal</td>
</tr>
<tr>
<td class="label">OCT2</td>
<td>Luminal</td>
</tr>
<tr>
<td class="label">OCT3</td>
<td>Abluminal</td>
</tr>
<tr>
<td class="label">MATE1</td>
<td>Luminal</td>
</tr>
<tr>
<td class="label">rs Number</td>
<td>Protein Change</td>
</tr>
<tr>
<td class="label">rs12239046</td>
<td>R61C</td>
</tr>
<tr>
<td class="label">rs34130495</td>
<td>P341L</td>
</tr>
<tr>
<td class="label">rs35599694</td>
<td>G401S</td>
</tr>
<tr>
<td class="label">rs59234583</td>
<td>V501F</td>
</tr>
</table>

{{.infobox .infobox-gene}}
Organic cation transporter 1 (OCT1). Mediates uptake of organic cations including neurotransmitters and drugs. Important for hepatic drug clearance. May transport neurotoxic compounds.

Pathway / Interaction Diagram

Gene Structure and Protein Architecture

Genomic Organization

The SLC22A1 gene is located on chromosome 11q13.4 and consists of 12 exons spanning approximately 27 kb of genomic DNA. The gene encodes a polytopic membrane protein with 12 predicted transmembrane domains, characteristic of the major facilitator superfamily (MFS). The promoter region contains binding sites for hepatocyte nuclear factors (HNFs) and other tissue-specific transcription factors, explaining its high expression in liver and kidney. [@koepsell2007]

Protein Topology

OCT1 contains characteristic features of MFS transporters:

The transport mechanism involves an alternating access model where the substrate binding site alternates between outward-facing and inward-facing conformations. [@nies2020]

Brain Expression and Blood-Brain Barrier Localization

Expression in the Central Nervous System

OCT1 is expressed at the blood-brain barrier (BBB) on the luminal (blood-facing) membrane of brain microvascular endothelial cells. This strategic localization enables:

• Drug uptake: Transport of cationic drugs from blood into the brain
• Neurotransmitter clearance: Potential clearance of monoamine neurotransmitters from the brain interstitial fluid
• Neurotoxin transport: Possible import of exogenous neurotoxic compounds

Expression levels vary across brain regions, with highest expression in:

• Cortex (particularly frontal cortex)
• Hippocampus
• Basal ganglia
• Cerebellum

Transport Kinetics at the BBB

The BBB expresses multiple organic cation transporters (OCT1, OCT2, OCT3, MATEs) that collectively determine CNS penetration of cationic drugs:

[@bacher2021]

Role in Parkinson's Disease

Dopamine Transport

OCT1 can transport dopamine, a key neurotransmitter lost in Parkinson's disease. At the BBB, OCT1-mediated transport may influence:

Therapeutic Implications for PD

OCT1 plays a significant role in Parkinson's disease pharmacotherapy:

• Levodopa transport: OCT1 mediates blood-to-brain transport of levodopa, affecting CNS bioavailability
• Dopamine agonists: Many PD drugs are OCT1 substrates
• Drug-drug interactions: Inhibitors of OCT1 can reduce CNS drug penetration

Neurotoxicity Risk

The potential for OCT1 to transport neurotoxic compounds is concerning:

• Endogenous neurotoxins: Potential transport of putatively toxic endogenous cations
• Environmental toxins: Some pesticides and industrial chemicals are organic cations
• Therapeutic safety: Overactive OCT1 could increase brain exposure to neurotoxic compounds

Role in Alzheimer's Disease

Choline Transport

OCT1 can transport choline, a precursor for acetylcholine synthesis. In Alzheimer's disease:

• Choline transport across the BBB may support cholinergic neuron function
• Impaired choline transport could contribute to cholinergic deficiency
• OCT1 activity may affect availability of acetylcholine precursors

Drug Delivery for AD Therapeutics

OCT1 significantly impacts CNS delivery of Alzheimer's drugs:

BBB Function in AD

AD pathology affects BBB integrity and transporter expression:

• Transport changes: Altered OCT1 expression in AD brain vasculature
• Inflammation effects: Neuroinflammation may modulate transporter function
• Therapeutic targeting: Modulating OCT1 could improve drug delivery

Pharmacogenomics

Genetic Variants

SLC22A1 polymorphisms significantly impact drug response:

[@dos2021]

Impact on Drug Therapy

Key drug interactions affected by OCT1 genotype:

Clinical Implications

Pharmacogenetic Testing

OCT1 genotyping is increasingly relevant for personalized medicine:

• Clinical testing available: Several labs offer SLC22A1 genotyping
• Dosing guidance: Variant information can guide initial dose selection
• Drug selection: Alternative drugs available for loss-of-function carriers

Drug-Drug Interactions

Multiple drugs affect OCT1 function:

Transport Kinetics

OCT1 exhibits polyspecificity, transporting diverse cations:

• Monoamine neurotransmitters: Dopamine, serotonin, histamine
• Environmental toxins: MPP+ (MPTP metabolite), paraquat
• Drugs: Antidiabetics, analgesics, antidepressants

Therapeutic Implications

Drug Development Considerations

Targeting OCT1 for CNS drug delivery:

• Pro-drug strategies: Design cationic pro-drugs for OCT1-mediated transport
• Inhibitor co-administration: Use OCT1 inhibitors to reduce peripheral exposure
• Species differences: Murine Oct1 has different substrate specificity

Pharmacological Modulation

[@nies2020]

Personalized Medicine

OCT1 genotyping can guide therapy:

• Dose adjustment: Variant carriers may require dose modifications
• Drug selection: Choose alternative drugs for loss-of-function variants
• Combination therapy: Consider OCT1 activity in multi-drug regimens

Interaction with Other Transporters

Solute Carrier Family

OCT1 belongs to the SLC22 family of organic cation transporters:

Transporter Networks

OCT1 operates in coordination with other transporters:

Clinical Biomarkers

Disease Monitoring

OCT1 expression may serve as a biomarker:

• BBB function: OCT1 levels indicate BBB transporter activity
• Drug response: Predicts CNS drug exposure
• Disease progression: Changes in AD/PD correlate with altered expression

Pharmacodynamic Markers

• Peripheral blood monocyte OCT1 expression as surrogate
• CSF transport activity measurements
• Imaging of transporter function

Summary

SLC22A1 encodes OCT1, a polyspecific organic cation transporter with critical roles in drug delivery to the brain. At the blood-brain barrier, OCT1 facilitates uptake of numerous pharmaceuticals, including Parkinson's disease medications like levodopa. Genetic variants of SLC22A1 significantly impact drug response, making it important for personalized medicine. While primarily expressed in liver and kidney, OCT1's presence at the BBB makes it particularly relevant for neurodegenerative disease therapy, where it influences both drug delivery and potential neurotoxin exposure.

Physiological Functions in the Liver

Hepatic Drug Metabolism

OCT1 plays a major role in hepatic drug uptake and metabolism. The liver is the primary site for drug metabolism, and OCT1 facilitates the entry of cationic drugs into hepatocytes where they can be metabolized by cytochrome P450 enzymes and other metabolic pathways. This function is critical for the first-pass metabolism of many orally administered drugs. [@jonker2001]

Key aspects of OCT1-mediated hepatic uptake include:

[@peacock2018]

Metformin Transport

One of the most clinically significant substrates of OCT1 is metformin, the first-line treatment for type 2 diabetes. OCT1-mediated hepatic uptake of metformin is essential for its glucose-lowering effects. The transport kinetics of metformin via OCT1 determine the drug's efficacy and duration of action. [@gal是可2004]

Genetic variants in SLC22A1 that reduce OCT1 function can lead to:

• Reduced metformin efficacy
• Altered dose requirements
• Variable therapeutic responses

Drug-Induced Liver Injury

OCT1 can mediate the hepatic uptake of potentially hepatotoxic compounds. Some drugs cause liver injury through OCT1-mediated uptake into hepatocytes, where they may cause:

• Direct oxidative stress
• Mitochondrial dysfunction
• Immune-mediated injury
• Induction of apoptosis

Understanding OCT1's role in drug-induced liver injury helps predict which patients may be at risk and guides the development of safer therapeutic agents.

Role in CNS Drug Delivery

Blood-Brain Barrier Transport

The blood-brain barrier (BBB) expresses organic cation transporters that significantly impact CNS drug delivery. OCT1 is strategically positioned on the luminal (blood-facing) side of brain microvascular endothelial cells, where it can mediate the uptake of organic cations into the brain. [@cecchelli2014]

The BBB expresses multiple organic cation transporters with distinct polarities:

[@abbott2010]

CNS Drug Transport Kinetics

The rate of drug transport across the BBB via OCT1 depends on several factors:

[@watanabe2021]

Drug Delivery Strategies

Understanding OCT1's role at the BBB enables strategic drug development:

• Pro-drug design: Creating cationic pro-drugs that are OCT1 substrates
• Drug selection: Choosing compounds with favorable OCT1 transport properties
• Combination therapy: Using OCT1 modulators to enhance or reduce brain penetration
• Personalized medicine: Matching drug selection to patient's OCT1 genotype

Pharmacogenomics of SLC22A1

Major Polymorphisms

SLC22A1 exhibits significant genetic variation that affects drug response:

[@dos2021]

Impact on Drug Response

Genetic variants in SLC22A1 significantly impact the pharmacokinetics and pharmacodynamics of many drugs:

Antidiabetic Drugs:

• Metformin response varies with SLC22A1 genotype
• R61C variant associated with reduced glycemic response

• Many antipsychotic drugs are OCT1 substrates
• Altered brain exposure affects efficacy and side effects
• [@shu2008]

• Platinum compounds are transported by OCT1
• [@takedomi2005]
• Reduced uptake may affect tumor cell killing

Clinical Implementation

Testing for SLC22A1 variants can guide therapy:

[@choudhury2007]

Role in Cancer Therapy

Tumor Drug Uptake

OCT1 expression in tumors can affect chemotherapy efficacy:

• Increased OCT1 expression can enhance drug uptake
• Some tumors rely on OCT1 for drug entry
• Variable expression affects treatment outcomes

Multi-Drug Resistance

Changes in OCT1 expression can contribute to drug resistance:

[@staud2013]

Structural Biology of OCT1

Topology and Structure

OCT1 belongs to the major facilitator superfamily (MFS) with characteristic features:

• 12 transmembrane α-helices
• N-terminus and C-terminus in the cytoplasm
• Large extracellular loops between helices 1-2 and 9-10
• Proton/cation antiport mechanism

Substrate Recognition

OCT1 exhibits broad substrate specificity:

Transport Mechanism

The transport cycle involves:

Disease Pathophysiology

Neurodegenerative Disease Implications

SLC22A1 variants and expression changes may influence neurodegenerative disease:

Parkinson's Disease:

• L-dopa transport across BBB affects treatment efficacy
• Genetic variants may contribute to variable response
• Drug-drug interactions at OCT1 important for polypharmacy

• Cholinesterase inhibitors may be OCT1 substrates
• BBB function changes in AD affect transporter activity
• Genetic variants could influence drug response

Metabolic Disease

OCT1 plays a well-established role in metabolic disease:

• Type 2 diabetes and metformin response
• Hepatic glucose metabolism
• Lipid metabolism
• Energy homeostasis

Research Methods and Tools

In Vitro Systems

Researchers use various systems to study OCT1:

• Cell lines: HEK293, CHO cells transfected with SLC22A1
• Primary cells: Hepatocytes, brain endothelial cells
• Xenopus oocytes: For electrophysiological studies
• Membrane vesicles: For transport kinetics

In Vivo Models

Mouse models provide insights into OCT1 function:

• Oct1 knockout mice: Show impaired drug uptake
• Humanized mice: Express human SLC22A1
• Transgenic models: Tissue-specific expression

Pharmacokinetic Analysis

Studies of OCT1 function employ:

• Uptake assays: Measure substrate accumulation
• Transport kinetics: Determine Km and Vmax
• Inhibition studies: Identify competitors
• Mass spectrometry: Quantify drug levels

Future Directions and Therapeutic Potential

Precision Medicine

OCT1 genotyping enables precision medicine approaches:

Novel Therapeutics

Drug development strategies targeting OCT1:

• Selective agonists: Enhance uptake of beneficial drugs
• Selective antagonists: Reduce uptake of toxic compounds
• Pro-drugs: Design OCT1-targeted pro-drugs
• Brain-penetrant drugs: Optimize for CNS delivery

Gene Therapy

Emerging approaches include:

• Viral vector-mediated OCT1 expression
• CRISPR-based gene editing
• RNA-based modulation

Environmental and Toxicological Considerations

Endogenous Substrates

OCT1 transports various endogenous compounds:

• Neurotransmitters: Dopamine, serotonin
• Hormones: Steroid derivatives
• Metabolites: Organic acid derivatives
• Signaling molecules: cAMP, cGMP

Xenobiotic Transport

OCT1 handles numerous foreign compounds:

• Drugs: Metformin, antipsychotics, chemotherapy
• Toxins: Environmental organic cations
• Pesticides: Some organophosphate compounds
• Heavy metals: Certain metal-organic complexes

Clinical Monitoring and Biomarkers

Pharmacodynamic Markers

Monitoring OCT1 activity involves:

• Plasma drug concentration measurements
• Liver function tests
• CNS drug penetration assessment
• Metabolic markers

Disease Biomarkers

OCT1 expression may serve as:

• Predictor of drug response
• Indicator of liver function
• Marker of BBB integrity
• Prognostic indicator in cancer

See Also

• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Organic Cation Transporters](/mechanisms/organic-cation-transport)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [SLC22 Family](/genes/slc22-family)
• [Drug Delivery to Brain](/therapeutics/brain-drug-delivery)

References

External Links

• [NCBI Gene: SLC22A1](https://www.ncbi.nlm.nih.gov/gene/6579)
• [UniProt: O15245](https://www.uniprot.org/uniprot/O15245)
• [Ensembl: ENSG00000175084](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000175084)
• [OMIM: 607607](https://www.omim.org/entry/607607)

Pathway Diagram

The following diagram shows the key molecular relationships involving slc22a1 discovered through SciDEX knowledge graph analysis: